Epigenetics & Cancer Genomics

The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our understanding of chromatin structure, histone modification, transcriptional activity and DNA methylation have resulted in an increasingly integrated view of epigenetics. In response to these insights, epigenetic therapy is expanding to include combinations of histone deacetylase inhibitors and DNA methyltransferase inhibitors. Zebularine, an orally administerable DNA methyltransferase inhibitor, has been a very promising recent addition to our arsenal of potentially useful drugs for epigenetic therapy. Epigenetics refers to alternate phenotypic states that are not based in differences in genotype, and are potentially reversible, but are generally stably maintained during cell division. The narrow interpretation of this concept is that of stable differential states of gene expression. 

The potential reversibility of epigenetic states offers exciting opportunities for novel cancer drugs that can reactivate epigenetically silenced tumor-suppressor genes. Epigenetic changes in cancer cells not only provide novel targets for drug therapy but also offer unique prospects for cancer diagnostics  The major interest in cancer epigenetics as a diagnostic tool is in localized epigenetic silencing. It is clear from this bird's-eye overview that the field of cancer epigeneticsis in flux. We can expect to see clinical implementation of both epigeneticcancer therapy and epigenetic cancer diagnostics in the next decade. Epigenetic control defects in cancer cells represent an emerging new area of investigation, where significant breakthroughs in the identification of the underlying molecular defects are anticipated in the next few years.

International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016, Birmingham, UK; Biotechnology World Convention, Aug 15-17, 2016, Sao Paulo, Brazil; International Conference on Synthetic Biology, Aug 18-19, 2016, London, UK, Annual Conference on Bio Science, Sept 12-13, 2016, Berlin, Germany; Noncoding RNAs in Health and Disease, February 21-24, 2016, Santa Fe, USA; Maintenance of Genome Stability March 7- 10, 2016, Panama, South America; Chromatin and Epigenetics, March 20-24, 2016 Whistler, Canada; Chromatin, Non-Coding RNAs and RNAP II Regulation in Development and Disease, March 29, 2016, Austin, USA; Chromatin Structure & Function, May 22-27, 2016, Les Diablerets, Switzerland

Epigenetic mechanisms act to change the accessibility of chromatin to transcriptional regulation locally and globally via modifications of the DNA and by modification or rearrangement of nucleosomes. Epigenetic gene regulation collaborates with genetic alterations in cancer development. This is evident from every aspect of tumour biology including cell growth and differentiation, cell cycle control, DNA repair, angiogenesis, migration, and evasion of host immunosurveillance. In contrast to genetic cancer causes, the possibility of reversing epigenetic codes may provide new targets for therapeutic intervention

Epigenetic programming is crucial in mammalian development, and stable inheritance of epigenetic settings is essential for the maintenance of tissue- and cell-type-specific functions. With the exception of controlled genomic rearrangements, such as those of the immunoglobulin and T-cell receptor genes in B and T cells, all other differentiation processes are initiated or maintained through epigenetic processes. Not surprisingly therefore, epigenetic gene regulation is characterized overall by a high degree of integrity and stability. 

  • Gene expression and epigenomics
  • Genes silencing
  • Cancer epigenetics
  • Cancer cells and genetic mutations
  • Cell based immunotherapy
  • Stem cell therapy for infectious diseases
  • Cell based immunosuppression in transplantation
  • Epigenetics of the antibody response
  • Epigenetic DNA repair and cancer

Related Conference of Epigenetics & Cancer Genomics

May 09-10, 2018

11th World Congress on Cell & Tissue Science

Tokyo, Japan
May 14-15, 2018

World Congress on Cell and Structural Biology

Osaka Japan
May 21-23, 2018

6th International Conference on Integrative Biology

Barcelona, Spain
June 04-06, 2018

12th Annual Conference on Stem Cell and Regenerative Medicine

Prague, Czech Republic
July 10-11, 2018

22nd World Congress on Biotechnology

Bangkok, Thailand
July 23-24, 2018

Annual Biotechnology Congress

Vancouver, British Columbia, Canada
October 08-09, 2018

10th Annual Conference on Stem Cell and Regenerative Medicine

Zurich, Switzerland
September 3-4, 2018

World Congress on Stem Cell Biology and Biobanking

Tokyo, Japan
September 10-11, 2018

22nd Global Biotechnology Congress

Stockholm, Sweden
September 17-18, 2018

6th Annual Congress on Biology and Medicine of Molecules

Abu Dhabi, UAE
September 19 - 20, 2018

2nd Annual summit on Cell Signaling and Cancer Therapy

Philadelphia, Pennsylvania, USA
September 19 - 20, 2018

2nd Annual summit on Cell Metabolism and Cytopathology

Philadelphia, Pennsylvania, USA
September 20-21, 2018

10 th Tissue Repair and Regeneration Congress

Dubai, UAE
September 21-22, 2018

11th International Conference on Genomics and Pharmacogenomics

Philadelphia, Pennsylvania, USA
September 21-22, 2018

5th International Conference on Human Genetics and Genetic Diseases

Philadelphia, Pennsylvania, USA
October 24-25, 2018

24th Biotechnology Congress: Research & Innovations

Boston, Massachusetts, USA
October 25-26, 2018

5th World Congress on Epigenetics and Chromosome

Istanbul, Turkey
November 2-3, 2018

International Congress & Expo on Genomics and Bioinformatics

Columbus, Ohio, USA
November 9-10, 2018

2nd Annual Summit on Stem Cell Research, Cell and Gene Therapy

Atlanta, Georgia, USA
Dec 03-04, 2018

3rd World Biotechnology Congress


(10 Plenary Forums - 1Event)
Sao Paulo, Brazil
March 18-19, 2019

11th World Congress and Expo on Cell & Stem Cell Research

Chicago, Illinois, USA

Epigenetics & Cancer Genomics Conference Speakers